AMGN
Amgen Inc
Company · XNAS · US · USD
Market price
$414.02
+$84.43 (+25.62%) · 3 months
| Date and time | Price |
|---|---|
| May 11, 2026 | $329.59 |
| May 12, 2026 | $332.66 |
| May 13, 2026 | $334.15 |
| May 14, 2026 | $336.59 |
| May 15, 2026 | $335.86 |
| May 18, 2026 | $324.39 |
| May 19, 2026 | $322.31 |
| May 20, 2026 | $331.18 |
| May 21, 2026 | $329.61 |
| May 22, 2026 | $339.95 |
| May 26, 2026 | $335.94 |
| May 27, 2026 | $336.06 |
| May 28, 2026 | $336.41 |
| May 29, 2026 | $336.77 |
| Jun 1, 2026 | $329.13 |
| Jun 2, 2026 | $328.34 |
| Jun 3, 2026 | $338.32 |
| Jun 4, 2026 | $345.62 |
| Jun 5, 2026 | $349.87 |
| Jun 8, 2026 | $345.73 |
| Jun 9, 2026 | $344.95 |
| Jun 10, 2026 | $337.68 |
| Jun 11, 2026 | $354.01 |
| Jun 12, 2026 | $355.29 |
| Jun 15, 2026 | $350.53 |
| Jun 16, 2026 | $347.78 |
| Jun 17, 2026 | $341.74 |
| Jun 18, 2026 | $337.45 |
| Jun 22, 2026 | $344.72 |
| Jun 23, 2026 | $346.91 |
| Jun 24, 2026 | $351.46 |
| Jun 25, 2026 | $352.79 |
| Jun 26, 2026 | $358.11 |
| Jun 29, 2026 | $360.55 |
| Jun 30, 2026 | $362.06 |
| Jul 1, 2026 | $361.12 |
| Jul 2, 2026 | $374.06 |
| Jul 6, 2026 | $366.44 |
| Jul 7, 2026 | $367.96 |
| Jul 8, 2026 | $368.03 |
| Jul 9, 2026 | $363.61 |
| Jul 10, 2026 | $363.59 |
| Jul 13, 2026 | $360.45 |
| Jul 14, 2026 | $355.29 |
| Jul 15, 2026 | $358.27 |
| Jul 16, 2026 | $371.59 |
| Jul 17, 2026 | $366.20 |
| Jul 20, 2026 | $364.17 |
| Jul 21, 2026 | $366.23 |
| Jul 22, 2026 | $366.22 |
| Jul 23, 2026 | $371.52 |
| Jul 24, 2026 | $375.70 |
| Jul 27, 2026 | $376.26 |
| Jul 28, 2026 | $393.01 |
| Jul 29, 2026 | $387.69 |
| Jul 30, 2026 | $387.78 |
| Jul 31, 2026 | $385.18 |
| Aug 3, 2026 | $378.87 |
| Aug 4, 2026 | $390.38 |
| Aug 5, 2026 | $407.70 |
| Aug 6, 2026 | $404.85 |
| Aug 7, 2026 | $410.91 |
| Aug 10, 2026 | $414.02 |
- Period change
- +25.62%
- Period low
- $322.31
- Period high
- $414.02
- Observations
- 63
- Updated
- Aug 10, 2026, 6:28 PM
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Company websiteClassifications
- Biotechnology · Biotech
- Pharmaceuticals · Pharma
- Healthcare
Market details
- Type
- Company
- Market
- XNAS
- Operating market
- XNAS
- Country
- US
- Currency
- USD
- Market capitalization
- $207,874,038,813.84
- Employees
- 31.5K